Home Nucleus Oncology U.S. Prostate Cancer Diagnostics Market to 2032

U.S. Prostate Cancer Diagnostics Market to 2032

Overview

The U.S. Prostate Cancer Diagnostics Market is expected to reach a 5.90 USD Billion by 2032 and is projected to grow at a CAGR of 17.10% from 2025 to 2032.

Revenue, 2024 (USD Billion)
2.20
Forecast, 2032 (USD Billion)
5.90
CAGR, 2024 - 2032
17.10%
Report Coverage
U.S.

U.S. Prostate Cancer Diagnostics Market 2018-2032 USD Billion

U.S. Prostate Cancer Diagnostics Market, Key Findings (2025-2032)

Market Growth and Projections:

  • Market Size (2024): 2.20 USD Billion
  • Projected Market Size (2032): 5.90 USD Billion
  • CAGR (2025-2032): 17.10%

Key Findings of U.S. Prostate Cancer Diagnostics Market

  • The U.S. Prostate Cancer Diagnostics Market was valued at 2.20 USD Billion in 2024.
  • The U.S. Prostate Cancer Diagnostics Market is likely to grow at a CAGR of 17.10% during the forecast period of 2024 to 2032.
  • In 2024, the Largest segment Prostatic Adenocarcinoma in Type Segment accounted for the largest share of the market with a revenue of 2.10 USD Billion
  • The fastest growing segment Castration-Resistant Prostate Cancer (Metastatic and Non-Metastatic) in Stage Segment grew Fastest with a CAGR of 19.06% during the forecast period from 2024 to 2032.

U.S. Prostate Cancer Diagnostics Market Scope

U.S. Prostate Cancer Diagnostics Market Segmentation & Scope
Product Type
  • Accessories
  • Instruments
  • Reagents & Consumables
Diagnostics Type
  • Confirmatory Tests
  • Preliminary Screening Tests
Stage
  • Recurrent/Advanced Prostate Cancer
  • Castration-Resistant Prostate Cancer (Metastatic and Non-Metastatic)
  • Localized Prostate Cancer
Sample Type
  • Others
  • Urine
  • Tissue
  • Blood
End User
  • Others
  • Cancer Research Institutes
  • Ambulatory Surgical Centers
  • Clinics
  • Hospitals
  • Independent Diagnostic Laboratories
Type
  • Others
  • Small Cell Carcinoma
  • Prostatic Adenocarcinoma
Age Group
  • Pediatric
  • Adult
  • Geriatrics
Distribution Channel
  • Retail Sales
  • Direct Tender

U.S. Prostate Cancer Diagnostics Market Data Coverage Insights

Study Period 2024-2032
Base Year 2022
Unit Revenue in USD Billion
Market Value in 2024 2.20 USD Billion
Market Value in 2032 5.90 USD Billion
CAGR (2025-2032) 17.10%
Historic Data 2016-2023
Market Segments Covered Product Type,Diagnostics Type,Stage,Sample Type,End User,Type,Age Group,Distribution Channel

Regional Insights:

  • Leading Market (2024-2032): U.S., leading in terms of revenue 2.20 USD Billion in 2024
    • Key Country: U.S., leading in terms of revenue with value of 2,200.92 USD Million in 2024.

Segments and Scope

  • U.S. Prostate Cancer Diagnostics Market to 2032, By Product Type
    • Reagents & Consumables is the largest segment in U.S. Prostate Cancer Diagnostics Market to 2032 with a revenue of 1.71 USD Billion in the year 2024.
    • Reagents & Consumables is the Fastest growing segment in U.S. Prostate Cancer Diagnostics Market to 2032 with a Growth rate of 17.55 % in forecast period 2025-2032.
  • U.S. Prostate Cancer Diagnostics Market to 2032, By Diagnostics Type
    • Preliminary Screening Tests is the largest segment in U.S. Prostate Cancer Diagnostics Market to 2032 with a revenue of 1.72 USD Billion in the year 2024.
    • Preliminary Screening Tests is the Fastest growing segment in U.S. Prostate Cancer Diagnostics Market to 2032 with a Growth rate of 17.65 % in forecast period 2025-2032.
  • U.S. Prostate Cancer Diagnostics Market to 2032, By Stage
    • Localized Prostate Cancer is the largest segment in U.S. Prostate Cancer Diagnostics Market to 2032 with a revenue of 1.70 USD Billion in the year 2024.
    • Castration-Resistant Prostate Cancer (Metastatic and Non-Metastatic) is the Fastest growing segment in U.S. Prostate Cancer Diagnostics Market to 2032 with a Growth rate of 16.83 % in forecast period 2025-2032.
  • U.S. Prostate Cancer Diagnostics Market to 2032, By Sample Type
    • Blood is the largest segment in U.S. Prostate Cancer Diagnostics Market to 2032 with a revenue of 1.77 USD Billion in the year 2024.
    • Blood is the Fastest growing segment in U.S. Prostate Cancer Diagnostics Market to 2032 with a Growth rate of 17.41 % in forecast period 2025-2032.
  • U.S. Prostate Cancer Diagnostics Market to 2032, By End User
    • Independent Diagnostic Laboratories is the largest segment in U.S. Prostate Cancer Diagnostics Market to 2032 with a revenue of 1.53 USD Billion in the year 2024.
    • Independent Diagnostic Laboratories is the Fastest growing segment in U.S. Prostate Cancer Diagnostics Market to 2032 with a Growth rate of 17.41 % in forecast period 2025-2032.
  • U.S. Prostate Cancer Diagnostics Market to 2032, By Type
    • Prostatic Adenocarcinoma is the largest segment in U.S. Prostate Cancer Diagnostics Market to 2032 with a revenue of 2.10 USD Billion in the year 2024.
    • Prostatic Adenocarcinoma is the Fastest growing segment in U.S. Prostate Cancer Diagnostics Market to 2032 with a Growth rate of 17.27 % in forecast period 2025-2032.
  • U.S. Prostate Cancer Diagnostics Market to 2032, By Age Group
    • Geriatrics is the largest segment in U.S. Prostate Cancer Diagnostics Market to 2032 with a revenue of 1.88 USD Billion in the year 2024.
    • Geriatrics is the Fastest growing segment in U.S. Prostate Cancer Diagnostics Market to 2032 with a Growth rate of 17.37 % in forecast period 2025-2032.
  • U.S. Prostate Cancer Diagnostics Market to 2032, By Distribution Channel
    • Direct Tender is the largest segment in U.S. Prostate Cancer Diagnostics Market to 2032 with a revenue of 1.83 USD Billion in the year 2024.
    • Direct Tender is the Fastest growing segment in U.S. Prostate Cancer Diagnostics Market to 2032 with a Growth rate of 17.74 % in forecast period 2025-2032.

U.S. Prostate Cancer Diagnostics Market Company Share Analysis

 
Company Name Company Share Analysis
Myriad Genetics, Inc.
OPKO Health, Inc.
Beckman Coulter, Inc.
Abbott
F. Hoffmann-La Roche Ltd.
U.S. Prostate Cancer Diagnostics Market Company Share Analysis

U.S. Prostate Cancer Diagnostics Market Geographical Sales Distribution, 2018-2032 USD Billion

U.S. Prostate Cancer Diagnostics Market Geographical Sales Distribution, 2018-2032 USD Billion

U.S. Prostate Cancer Diagnostics Market Company Profiling

U.S. Prostate Cancer Diagnostics Market Company Profiling

Industry Related Reports

Asia-Pacific Breast Lesion Localization Methods Market
Europe Breast Lesion Localization Methods Market
North America Breast Lesion Localization Methods Market
Middle East & Africa Breast Lesion Localization Methods Market
South America Breast Lesion Localization Methods Market
Australia Breast Lesion Localization Methods Market
Belgium Breast Lesion Localization Methods Market
Brazil Breast Lesion Localization Methods Market
Canada Breast Lesion Localization Methods Market
China Breast Lesion Localization Methods Market
Frequently Asked Questions
The U.S. Prostate Cancer Diagnostics Market is segmented based on Segmentation Product Type,Diagnostics Type,Stage,Sample Type,End User,Type,Age Group,Distribution Channel.
U.S. Prostate Cancer Diagnostics Market was valued at USD 2.20(Revenue in USD Billion) in 2022.
U.S. Prostate Cancer Diagnostics Market is projected to grow at a CAGR of 17.10% during the forecast period of 2024 to 2032.
The Prostatic Adenocarcinoma segment is expected to dominate the U.S. Prostate Cancer Diagnostics Market, holding a largest market share of 2.10 USD Billion in 2024

U.S. Prostate Cancer Diagnostics Market Scope

U.S. Prostate Cancer Diagnostics Market Segmentation & Scope
Product Type
  • Accessories
  • Instruments
  • Reagents & Consumables
Diagnostics Type
  • Confirmatory Tests
  • Preliminary Screening Tests
Stage
  • Recurrent/Advanced Prostate Cancer
  • Castration-Resistant Prostate Cancer (Metastatic and Non-Metastatic)
  • Localized Prostate Cancer
Sample Type
  • Others
  • Urine
  • Tissue
  • Blood
End User
  • Others
  • Cancer Research Institutes
  • Ambulatory Surgical Centers
  • Clinics
  • Hospitals
  • Independent Diagnostic Laboratories
Type
  • Others
  • Small Cell Carcinoma
  • Prostatic Adenocarcinoma
Age Group
  • Pediatric
  • Adult
  • Geriatrics
Distribution Channel
  • Retail Sales
  • Direct Tender
Frequently Asked Questions
The U.S. Prostate Cancer Diagnostics Market is segmented based on Segmentation Product Type,Diagnostics Type,Stage,Sample Type,End User,Type,Age Group,Distribution Channel.
U.S. Prostate Cancer Diagnostics Market was valued at USD 2.20(Revenue in USD Billion) in 2022.
U.S. Prostate Cancer Diagnostics Market is projected to grow at a CAGR of 17.10% during the forecast period of 2024 to 2032.
The estimated market value of the U.S. Prostate Cancer Diagnostics Market for final year is USD 5.90 (USD Billion).

U.S. Prostate Cancer Diagnostics Market Company Profiling

U.S. Prostate Cancer Diagnostics Market Company Profiling
Frequently Asked Questions
The U.S. Prostate Cancer Diagnostics Market is segmented based on Segmentation Product Type,Diagnostics Type,Stage,Sample Type,End User,Type,Age Group,Distribution Channel.
U.S. Prostate Cancer Diagnostics Market was valued at USD 2.20(Revenue in USD Billion) in 2022.
U.S. Prostate Cancer Diagnostics Market is projected to grow at a CAGR of 17.10% during the forecast period of 2024 to 2032.
The estimated market value of the U.S. Prostate Cancer Diagnostics Market for final year is USD 5.90 (USD Billion).

Related Markets

HAVE A QUESTION?

Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.

BROWSE RELATED PAGES